[1] Song H*, Wu J*, Tang Y*, Dai Y* ... Lu M#. Sci Transl Med 2023, 15:eabn9155. 五年影响因子22.2
[2] Chen S*, Wu J*, Liang Y* ... Lu X#, Chen S#, Lu M#. Cancer Cell 2021;39(2):225-239.e8. 五年影响因子41.2
[3] Tang Y*, Song H*, Wang Z*, Xiao S* ... Liu F#, Wu Y#, Lu M#. Cell Rep 2022;39(2):110622. 五年影响因子 11.0
[4] Wang Z*, Zhao Y*, Wang Q*, Xing Y* ... Zhang L#, Yang H#, Lu M#. STTT 2021;6(1):214. 五年影响因子35.1
[5] Yan N*, Li Y*... Lu M#. EMBO Rep 2022;23(6):e54147. 五年影响因子10.5
[6]Yan Q*, Sun R*, Cui Z*... Lu M#, Zhu Y#, Fan C#. (2022). Nano Today 2022;47:101649. 五年影响因子20.2
[7]Wu J*, Li Y*, Wu J*... Zhang S#, Chang C#, Lu M#. Clin Transl Med 2021;11(11):e593. 五年影响因子9.1
[8] Wu J*, Chen S*, Lu M#. J Mol Cell Biol 2021;13(2):155-157. 五年影响因子7.4
[9] Wu J*, Liang Y* ... Lu M#. Cell Signal 2020;67:109508. 五年影响因子4.6
[10]Chen S*, Wu J* ... Chen Z#, Lu M#, Jones EY#, Lu X#. PNAS 2019;116(35):17470-17479. 五年影响因子13.5

[1] Lu M*, Zak J, Chen S, Sanchez-Pulido L, Severson DT, Endicott J, Ponting CP, Schofield CJ, Lu X#. Cell 2014;157(5):1130-1145. 五年影响因子59.9004

[2] Lu M*, Breyssens H, Salter V, Zhong S, Hu Y, Baer C, Ratnayaka I, Sullivan A, Brown NR, Endicott J, Knapp S, Kessler BM, Middleton MR, Siebold C, Jones EY, Sviderskaya EV, Cebon J, John T, Caballero OL, Goding CR, Lu X#. Cancer Cell 2013;23(5):618-633. 五年影响因子41.1601

[3] Lu M*, Muers MR, Lu X#. Nat Rev Mol Cell Biol 2016;17(8):523-532. 五年影响因子97.0063

[4] Qin Y*, Dai W, Wang Y, Gong X#, Lu M#. Biochem Biophys Res Commun 2013;431(2):169-175. 五年影响因子3.4980

[5] Lu M*, Gong X, Lu Y, Guo J, Wang C, Pan Y#. J Biol Chem 2006;281(19):13620-13627. 五年影响因子5.2953

1、Lu, Min; Wu, Jiale; Song, Huaxin. PANDA as a novel therapeutic, PCT/CN2018/085190。该专利进入中国2020071600684380；进入美国16959906；进入欧盟（28国）EP18898022.1；进入日本3148-PCT-JP；进入澳大利亚2018399726；进入加拿大0146523-00002。该专利部分国家地区使用权完成许可转化。该专利获第六届全国临床创新与发明大赛总决赛一等奖

2、Lu, Min; Wu, Jiale; Song, Huaxin. mp53 rescue compounds and methods of treating a p53 disorder, PCT/CN2019/070117。该专利进入中国2020071600808010；进入美国16959894；进入欧盟（28国）EP19736093.6；进入日本3147-PCT-JP；进入澳大利亚2019205062；进入加拿大0146523-00001

3、卢敏，梁颖，肖淑君，宋花歆；多功能p53复活药物及其用途，202110659536.4

4、卢敏，宋花歆；一种筛选适合用p53复活药物治疗p53异常相关疾病病人的方法，202110659578.8

5、Lu, Xin; Lu, Min. iASPP phosphorylation and metastatic potential. WIPO, WO 2013/131019 A1

1、临床试验Arsenic Trioxide in Refractory Solid Tumors with Rescuable p53 Mutation (https://www.clinicaltrials.gov/ct2/show/NCT04869475)

2、临床试验Mutant p53-based Personalized Trial Using Decitabine and Arsenic Trioxide on AML/MDS (https://www.clinicaltrials.gov/ct2/show/NCT03855371)

3、临床试验Sodium Stibogluconate in the MDS/AML With One of the 65 Defined p53 Mutations (https://www.clinicaltrials.gov/ct2/show/NCT04906031)

4、TP53 Trust介绍（http://tp53.co.uk/interview-with-min-lu/）

5、AntiCancer Fund介绍（https://www.anticancerfund.org/en/blog/latest-news-about-drug-repurposing-oncology-4）